Valuation: Autolus Therapeutics plc

Market Cap 405M 362M 333M 302M 564M 38.41B 575M 3.97B 1.6B 20.21B 1.52B 1.49B 63.72B P/E 2026 *
-1.87x
P/E 2027 * -2.2x
Enterprise Value 252M 226M 208M 188M 352M 23.95B 358M 2.48B 995M 12.6B 947M 926M 39.73B EV / Sales 2026 *
1.68x
EV / Sales 2027 * 1.71x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day-3.80%
1 week-1.30%
1 month-21.65%
3 months+2.01%
6 months+7.80%
Current year-23.62%
1 week 1.48
Extreme 1.48
1.65
1 month 1.48
Extreme 1.48
1.88
Current year 1.18
Extreme 1.175
2.58
1 year 1.18
Extreme 1.175
2.58
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/09/2014
Chief Executive Officer 61 01/03/2016
Director of Finance/CFO 56 07/08/2023
Director TitleAgeSince
Chairman 61 01/10/2014
Director/Board Member 78 01/08/2014
Director/Board Member 71 01/03/2018
Date Insider Type Main position Quantity % Market Cap. Importance
2/9/26 Sell

Executive/Senior Manager

-6,713 0.0025%
29/6/26 Free

Director

79,167 0.0477%
18/3/26 Other

Chief Executive Officer

6,917,877 4.1641%
Change 5-day change 1-year change 3-year change Capi.($)
-3.80%-1.30%-1.94%-46.10% 405M
+3.19%+11.31%+64.28%+155.91% 1,263B
-0.73%+3.56%+44.65%+84.17% 658B
+1.41%+3.24%+35.25%+108.88% 521B
+0.42%+3.20%+55.81%+72.50% 391B
+2.18%+2.93%+73.90%+45.59% 369B
+1.12%+4.52%+34.76%+58.24% 307B
+6.96%+8.86%+11.95%+36.20% 290B
+1.15%+6.09%+56.15%+82.25% 252B
+3.06%+9.38%+42.48%+117.32% 212B
Average +1.50%+5.18%+41.73%+71.50% 426.23B
Weighted average by Cap. +2.01%+6.60%+50.50%+100.42%

Financials

2026 *2027 *
Net sales 150M 134M 123M 112M 209M 14.22B 213M 1.47B 591M 7.48B 562M 550M 23.59B 192M 172M 159M 144M 268M 18.27B 274M 1.89B 759M 9.61B 722M 707M 30.31B
Net income -220M -197M -181M -164M -307M -20.88B -313M -2.16B -867M -10.98B -825M -808M -34.63B -187M -168M -154M -140M -262M -17.8B -266M -1.84B -739M -9.36B -704M -689M -29.53B
Net Debt -152M -136M -126M -114M -213M -14.47B -217M -1.5B -601M -7.61B -572M -560M -24B -75.11M -67.27M -61.88M -56.07M -105M -7.13B -107M -738M -296M -3.75B -282M -276M -11.83B
Projected Income Statement - Annual - Autolus Therapeutics plc
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
30/10/26 USD 1.520 -3.80% 1,675,291
29/10/26 USD 1.580 -3.07% 2,347,068
28/10/26 USD 1.630 +5.16% 1,394,966
27/10/26 USD 1.550 +1.31% 1,785,030
26/10/26 USD 1.530 -0.65% 1,237,586
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Autolus Therapeutics plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
1.520USD
Average target price
8.750USD
Spread / Average Target
+475.66%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Autolus Therapeutics plc
  1. Stock Market
  2. Stocks
  3. AUTL Stock